EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Proteolysis‐Targeting Chimera (PROTAC): Current Applications and Future Directions

Gang Fan, Shilin Chen, Qingping Zhang, Na Yu, Ziyang Shen, Zhaoji Liu, Weiming Guo, Zhihan Tang, Jing Yang, Miao Liu

MedComm · 2025-10 · 6 (10)

DOI: 10.1002/mco2.70401 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift MedComm, online erschienen am 04.10.2025. Verfasst von Gang Fan und 9 weiteren Autor:innen. Beteiligte Einrichtung: Medical Research Center Affiliated Nanshan Hospital of Shenzhen University Shenzhen China. Die Arbeit wurde bisher 49-mal zitiert (Crossref) und nennt 453 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Guangdong Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Targeted protein degradation (TPD) represents a paradigm shift in drug discovery, moving beyond traditional binding‐based inhibition toward active removal of disease‐driving proteins. This approach has unlocked therapeutic possibilities for previously “undruggable” targets, including transcription factors like MYC and STAT3, mutant oncoproteins such as KRAS G12C, and scaffolding molecules lacking conventional binding pockets. Among TPD strategies, proteolysis‐targeting chimeras (PROTACs) have emerged as the leading clinical platform, with the first molecule entering trials in 2019 and progression to Phase III completion by 2024. This comprehensive review examines PROTAC development across diverse therapeutic areas, analyzing key targets including kinases, hormone receptors, antiapoptotic proteins, and epigenetic modulators. We evaluate clinical progression of breakthrough candidates such as ARV‐110 for prostate cancer, ARV‐471 for breast cancer, and BTK degraders, while discussing critical challenges including the “hook effect” and oral bioavailability limitations. The review explores future directions encompassing innovative delivery strategies, tissue‐specific degrader design, and approaches for expanding E3 ligase repertoires and overcoming resistance. This review provides essential foundations for rational target selection, molecular optimization, and clinical translation strategies. By integrating mechanistic insights with clinical realities, this analysis offers perspectives on PROTAC technology advancement and identifies opportunities for transforming treatment of complex diseases resistant to conventional therapies.

Schlagwörter

Stichwörter der Autor:innen

PROTACclinical translationdrug discoverytarget protein degradationubiquitin–proteasome system

Autor:innen und Institutionen

  • Medical Research Center Affiliated Nanshan Hospital of Shenzhen University Shenzhen China.
  • Pan-Vascular Research Group Affiliated Nanshan Hospital of Shenzhen University Shenzhen China.
  • Department of Endocrinology Affiliated Nanshan Hospital of Shenzhen University Shenzhen China.
  • Department of Neurosurgery Affiliated Nanshan Hospital of Shenzhen University Shenzhen China.
  • Department of Biology Boston University Boston Massachusetts USA.
  • Department of Pathology Brigham and Women's Hospital Harvard Medical School Boston Massachusetts USA.

Förderung

  • National Natural Science Foundation of China
  • Natural Science Foundation of Guangdong Province

Zitieren

APA

Fan, G., Chen, S., Zhang, Q., Yu, N., Shen, Z., Liu, Z., Guo, W., Tang, Z., Yang, J., & Liu, M. (2025). Proteolysis‐Targeting Chimera (PROTAC): Current Applications and Future Directions. MedComm, 6(10). https://doi.org/10.1002/mco2.70401

Vancouver

Fan G, Chen S, Zhang Q, Yu N, Shen Z, Liu Z, et al. Proteolysis‐Targeting Chimera (PROTAC): Current Applications and Future Directions. MedComm. 2025;6(10). doi:10.1002/mco2.70401

BibTeX
@article{Fan2025,
  author = {Fan, Gang and Chen, Shilin and Zhang, Qingping and Yu, Na and Shen, Ziyang and Liu, Zhaoji and Guo, Weiming and Tang, Zhihan and Yang, Jing and Liu, Miao},
  title = {Proteolysis‐Targeting Chimera (PROTAC): Current Applications and Future Directions},
  journal = {MedComm},
  year = {2025},
  volume = {6},
  number = {10},
  doi = {10.1002/mco2.70401}
}
Kostenlos starten →